CCS Heart Failure: Acute Decompensation vs Chronic Management

SEO Title: CCS Heart Failure Cases | HFrEF CHF Management Step 3 (2026)

Meta Description: Master CCS heart failure: HFrEF vs HFpEF, acute decompensation management, GDMT (ACEi, beta-blockers, MRA, SGLT2i), ICD/CRT indications.

Target Keywords: CCS heart failure, CCS CHF management, step 3 CCS heart failure, CCS acute decompensated heart failure

URL Slug: ccs-heart-failure-acute-chronic

Opening

Heart failure cases are ubiquitous on Step 3 CCS exams, appearing as both primary problems and comorbidities complicating management of other conditions. Examiners test your ability to distinguish heart failure with reduced ejection fraction (HFrEF) from preserved ejection fraction (HFpEF), rapidly stabilize acute decompensation with IV diuretics and vasodilators, optimize chronic therapy with guideline-directed medical therapy (GDMT), and recognize when device therapy (ICD/CRT) is indicated. The clinical pearl that separates strong candidates is understanding that HFrEF requires specific neurohormonal blockade with ACE inhibitors (or ARNi), beta-blockers, mineralocorticoid receptor antagonists, and now SGLT2 inhibitors—each with proven mortality benefit. This comprehensive guide covers the complete spectrum of heart failure management from acute decompensation through chronic optimization.

Classification: HFrEF vs HFpEF

Heart failure classification is based on left ventricular ejection fraction (LVEF) measured on echocardiography.

HFrEF: Specific GDMT Evidence-Based

Only HFrEF has proven GDMT agents with mortality benefit. HFpEF has limited pharmacotherapy; management focuses on symptom control and comorbidity optimization.

Acute Decompensated Heart Failure (ADHF): Recognition and Initial Workup

Clinical Presentation

Pulmonary Edema (congestive symptoms):

• Dyspnea at rest or exertional

• Orthopnea (difficulty breathing when lying flat; requires 2+ pillows)

• Paroxysmal nocturnal dyspnea (PND; awakens from sleep gasping for breath)

• Rales on lung exam

Peripheral Edema (systemic congestion):

• Peripheral pitting edema (bilateral lower extremities, or presacral if bedridden)

• Elevated jugular venous pressure (JVP >8 cm)

• Hepatojugular reflux (pressing right upper abdomen increases JVP)

• Hepatomegaly with right upper quadrant tenderness

Low-Output Symptoms:

• Fatigue, weakness

• Hypotension (SBP <90 mmHg suggests cardiogenic shock)

• Oliguria, altered mental status (in severe decompensation)

Diagnostic Workup

Labs:

• B-type natriuretic peptide (BNP) or NT-proBNP: Elevated in heart failure; BNP >400 pg/mL or NT-proBNP >2000 pg/mL supports diagnosis

• Troponin: Screen for acute coronary syndrome triggering decompensation

• Complete metabolic panel (CMP): Assess renal function (Cr), electrolytes (K, Na, Mg), glucose

• Complete blood count (CBC): Anemia common; may impair oxygen delivery

• Liver function tests (LFTs): Hepatic congestion raises transaminases; cholestasis if severe

• Echocardiography: Assess LVEF (HFrEF vs HFpEF), ventricular size, diastolic function, valvular disease, pericardial effusion

Imaging:

• Chest X-ray: Pulmonary edema (interstitial or alveolar infiltrates), cardiomegaly, pleural effusions

• EKG: Screen for acute MI (ST elevation, T-wave changes), arrhythmia (new AF may trigger decompensation)

Triggers for ADHF

Identify and address:

• Medication non-compliance (most common)

• Dietary sodium excess (common precipitant)

• Acute coronary syndrome (ACS)

• Uncontrolled hypertension (sudden increase in afterload)

• New-onset arrhythmia (rapid AF, ventricular tachycardia)

• Pneumonia or other infection/sepsis

• Renal dysfunction (reduced clearance of fluid/sodium)

• Pregnancy (peripartum cardiomyopathy)

• Thyrotoxicosis (increased metabolic rate)

> Study Tip: ADHF trigger identification is tested frequently. The StudyCCS question bank includes 16+ acute heart failure cases where you must identify decompensation triggers, order appropriate workup, initiate IV therapy, and avoid common pitfalls with real-time grading.

Acute Decompensated Heart Failure: Stabilization Protocol

Oxygen and Respiratory Support

Goal SpO2: ≥90% (avoid hypoxemia worsening contractility)

Escalation:

• Nasal cannula (up to 6 L/min)

• Non-rebreather mask (up to 15 L/min)

• CPAP/BiPAP: If respiratory distress; improves afterload reduction and oxygenation (avoid if SBP <90)

• Intubation: If respiratory failure despite above; increases intrathoracic pressure, further reducing preload and afterload

IV Diuretics: First-Line for Congestive ADHF

Agent: Furosemide (most widely used)

Dosing:

• Initial: 40-80 mg IV (or 2.5× home PO dose if on chronic diuretics)

• Repeat boluses: Q1-2H based on urine output and clinical response

• Continuous infusion: 5-10 mg/hr if inadequate bolus response (may be more effective for resistant cases)

Goal: Achieve negative fluid balance (500-1000 mL/day loss); reduce JVP, clear rales, improve dyspnea

Monitoring:

• Daily weights (goal 1-2 lb/day loss)

• Strict I&Os (measure urine, all IV fluids, insensible losses)

• Serum creatinine and electrolytes (ensure no worsening renal function or hypokalemia)

• Orthostatic vital signs before discharge (orthostatic hypotension signals over-diuresis)

Worsening renal function on diuretics:

• May indicate excessive volume depletion or cardiogenic shock (worsening perfusion)

• Consider holding diuretics, reduce dose, or add vasodilator to improve forward flow

• If persistent azotemia despite optimization, consider ultrafiltration/dialysis

Vasodilators: Improve Hemodynamics in ADHF

IV Nitrates (Nitroglycerin):

• Mechanism: Venous dilation (reduces preload); some arterial dilation (reduces afterload)

• Dosing: IV infusion 10-200 mcg/min; titrate by 10-20 mcg every 3-5 min to BP tolerance and symptom relief

• Advantages: Rapid onset, easily titrated, reversible

• Disadvantages: Tachyphylaxis (tolerance develops within 24-48 hours); avoid in RV infarction (nitrates drop RV preload, worsening output)

• Monitoring: Hourly BP checks; hold if SBP <90 or headache severe

IV Vasodilators (Sodium Nitroprusside):

• Mechanism: Balanced arterial and venous dilation; powerful afterload reduction

• Dosing: 0.3-5 mcg/kg/min IV infusion; titrate to BP and symptom response

• Advantages: Potent afterload reduction; useful in hypertensive ADHF with pulmonary edema

• Disadvantages: Hypotension risk, thiocyanate toxicity (monitor if >72 hours), cyanide toxicity (especially renal failure)

• Monitoring: Continuous BP monitoring (intraarterial line preferred); daily thiocyanate level if >72 hours

Inotropes and Vasopressors: Reserved for Cardiogenic Shock

Cardiogenic shock: Forward flow inadequate (SBP <90, oliguria, altered mental status, cool extremities) despite diuretics and vasodilators.

Dobutamine:

• Mechanism: Beta-1 agonist → increased contractility; some beta-2 effects → peripheral vasodilation

• Dosing: 2-20 mcg/kg/min IV infusion

• Use: Low-output ADHF with hypotension; improves cardiac output and urine perfusion

• Risk: Tachycardia, arrhythmias (especially supraventricular), increased myocardial oxygen demand (worsens ischemia if CAD)

Milrinone:

• Mechanism: Phosphodiesterase-3 inhibitor → positive inotrope + vasodilation (inodilator)

• Dosing: 0.25-0.75 mcg/kg/min IV infusion

• Use: Low-output ADHF; preferred if hypotension limits beta-agonist use

• Risk: Hypotension, arrhythmias, tachyphylaxis

Norepinephrine (Levophed):

• Mechanism: Alpha-1 and beta-1 agonist → vasoconstriction and increased contractility

• Dosing: 0.01-3 mcg/kg/min IV infusion

• Use: Cardiogenic shock with hypotension unresponsive to dobutamine/milrinone

• Risk: Intense vasoconstriction may worsen peripheral perfusion, increase afterload (adverse in heart failure)

ICU monitoring: All inotropes and vasopressors require ICU-level care with continuous cardiac monitoring, intraarterial BP monitoring, and frequent reassessment.

Mechanical Support Devices (If Medical Management Fails)

Intra-aortic Balloon Pump (IABP):

• Decreases afterload, increases coronary perfusion

• Temporizing measure (days to weeks) while optimizing medical therapy or awaiting transplant/mechanical support

• Bridge to recovery or transplant

Extracorporeal Membrane Oxygenation (ECMO) and Ventricular Assist Devices (VAD):

• Used in fulminant cardiogenic shock unresponsive to inotropes

• Require ICU, specialized centers

• Bridge to recovery or transplant

> Practice Alert: Acute decompensation management and cardiogenic shock protocols are high-yield CCS topics. The StudyCCS question bank includes cases where you must titrate IV diuretics, choose vasodilators vs inotropes, and recognize cardiogenic shock requiring ICU escalation.

Chronic Heart Failure: Guideline-Directed Medical Therapy (GDMT) for HFrEF

Goal: Slow disease progression, prevent hospitalizations, improve survival. All agents below have randomized trial evidence for mortality benefit in HFrEF.

ACE Inhibitor (or ARNi) — First-Line

Mechanism: Block angiotensin II-mediated vasoconstriction, aldosterone secretion, and myocardial remodeling

Agents:

• ACE inhibitor: Enalapril, lisinopril, ramipril (most studied)

◦ Starting dose: Low (e.g., enalapril 2.5 mg BID), uptitrate every 1-2 weeks to target (e.g., enalapril 10 mg BID)

• Angiotensin II Receptor Blocker (ARB): Losartan, valsartan (alternative if ACE cough)

◦ Starting dose: Low (e.g., losartan 25 mg daily), uptitrate to target

• ARNI (Angiotensin Receptor-Neprilysin Inhibitor): Sacubitril/valsartan (preferred if available/affordable)

◦ Combines ARB effect with neprilysin inhibition (increases natriuretic peptides → vasodilation, reduced fibrosis)

◦ Starting dose: 24/26 mg BID, titrate to 97/103 mg BID

◦ More effective than ACE inhibitor monotherapy (PARADIGM-HF trial); preferred first-line if tolerated

Monitoring:

• Check potassium and creatinine at baseline, 1 week, 1 month, then Q3 months

• Watch for hyperkalemia (K >5.5 mEq/L) and worsening renal function (Cr rise >30%)

• Cough common with ACE inhibitors; usually resolves with lower dose or switch to ARB/ARNI

• Avoid combining ACE-I/ARB with NSAIDs (increased renal dysfunction and hyperkalemia risk)

Contraindications:

• Hyperkalemia (K >5.5)

• Severe renal disease (eGFR <30 mL/min; use with caution; monitor closely)

• History of angioedema

• Pregnancy (teratogenic; especially 2nd/3rd trimester)

Beta-Blocker — Essential Second-Line Agent

Mechanism: Blocks sympathetic overstimulation; reduces heart rate and contractility (decreases myocardial oxygen demand)

Agents (HF-proven):

• Metoprolol succinate (Toprol XL, extended-release only; NOT tartrate): Start 12.5 mg daily, titrate to 190 mg daily

• Carvedilol (Coreg): Start 3.125 mg BID, titrate to 25 mg BID

• Bisoprolol: Start 1.25 mg daily, titrate to 10 mg daily

Important: Carvedilol and metoprolol succinate have proven mortality benefit in HFrEF; atenolol and metoprolol tartrate do NOT.

Uptitration:

• Increase dose every 2-4 weeks as tolerated

• Monitor HR (target <70 bpm if possible; >50 acceptable)

• Avoid abrupt discontinuation (can cause acute decompensation)

Common side effects:

• Fatigue, dizziness, hypotension (usually transient)

• Bradycardia, AV block (hold if HR <50 or AV block develops)

Monitoring:

• HR and BP at each uptitration

• Check LVEF after 3 months of therapy (may improve with beta-blocker + ACE-I/ARNi)

Mineralocorticoid Receptor Antagonist (MRA) — Third-Line

Mechanism: Blocks aldosterone effects on renal sodium reabsorption and myocardial fibrosis

Agents:

• Spironolactone: Start 12.5-25 mg daily, titrate to 25-50 mg daily

• Eplerenone: Start 25 mg daily, titrate to 50 mg daily (more specific MRA; fewer sexual side effects than spironolactone)

Indications:

• LVEF ≤35% (standard)

• Recent MI with reduced LVEF and HF or diabetes (eplerenone in EPHESUS trial)

• LVEF ≤40% if symptoms persist despite ACE-I/ARNi and beta-blocker

Monitoring:

• Potassium and creatinine at baseline, 3 days, 1 week, 1 month, then Q3 months (hyperkalemia major risk, especially with concurrent ACE-I/ARB)

• Hold if K >5.5 mEq/L or Cr rise >30%

• Gynecomastia and sexual dysfunction common with spironolactone (eplerenone preferred if problematic)

SGLT2 Inhibitor — Emerging Game-Changer

SGLT2i (empagliflozin, dapagliflozin, canagliflozin) have proven mortality/hospitalization benefit in HFrEF and even HFpEF.

Mechanism: Inhibit renal glucose reabsorption; increase natriuresis and reduce cardiac preload; improve metabolic parameters

Agents and Dosing:

• Dapagliflozin: 10 mg daily

• Empagliflozin: 10 mg daily

• Canagliflozin: 100-300 mg daily

Benefits:

• Reduce HF hospitalizations by ~25%

• Reduce progression to severe HF

• Mortality benefit in several trials (DAPA-HF, EMPEROR-Reduced)

• Weight loss, improved glucose control (if diabetic)

• Improved LVEF (some patients)

• Safe in moderate-to-severe renal disease (eGFR 20-60; empagliflozin studied in eGFR <20)

Side effects:

• Genital mycotic infections (candida)

• Euglycemic diabetic ketoacidosis (rare; warn patients on insulin about sick days)

• Volume depletion (especially if high-dose diuretics)

Monitoring:

• Renal function at baseline and periodically

• Warn about sick days and infection symptoms

• Educate on proper hygiene to prevent genital infections

Current position in GDMT:

• Add to ACE-I/ARNi, beta-blocker, and MRA if still symptomatic or EF <35%

• Some guidelines now recommend SGLT2i earlier (after ACE-I/ARNi + beta-blocker) given mortality benefit

Ivabradine (Heart Rate Reduction Agent)

Mechanism: Selective If channel inhibitor; slows heart rate without negative inotropic effect

Indications:

• HFrEF (LVEF ≤35%) with sinus rhythm and HR ≥70 bpm despite optimal beta-blocker therapy

• Reduces HF hospitalizations and mortality (SHIFT trial)

Dosing: Start 5 mg BID, titrate to 7.5 mg BID; hold if HR <55

Monitoring: HR and EKG (avoid if QTc >500 ms)

Less commonly used than SGLT2i currently.

HFpEF Management

HFpEF (preserved EF ≥50%) lacks proven mortality-reducing pharmacotherapy. Management focuses on:

1. Symptom relief: Diuretics for congestion

2. Comorbidity optimization:

◦ Hypertension: Aggressive BP control (target <130/80); ACE-I or ARB reasonable

◦ Diabetes: SGLT2i (empagliflozin, dapagliflozin show benefit in HFpEF)

◦ Atrial fibrillation: Rate control with beta-blocker or calcium channel blocker; anticoagulation if CHA2DS2-VASc ≥2

◦ Obesity: Weight loss program

3. Sodium and fluid restriction: 2 g/day sodium, <2 L fluid intake

4. Exercise: Cardiac rehabilitation, supervised exercise improves functional capacity

Device Therapy: ICD and CRT Indications

Implantable Cardioverter-Defibrillator (ICD)

Indication (Primary Prevention):

• LVEF ≤35% on optimal GDMT × ≥40 days post-MI (or anytime if non-ischemic)

• Reduces sudden cardiac death from ventricular fibrillation

Indication (Secondary Prevention):

• History of ventricular fibrillation or sustained ventricular tachycardia (VT)

Procedure: Generator implanted in upper left chest with transvenous lead(s) to right ventricle

Cardiac Resynchronization Therapy (CRT)

Indication (CRT-P, pacemaker):

• LVEF ≤35%

• QRS duration ≥120 ms (indicates dyssynchrony; electrical delays in ventricular conduction)

• Improves contractility, reduces HF symptoms, reduces hospitalizations and mortality

Indication (CRT-D, defibrillator + pacemaker):

• LVEF ≤35% AND high risk for sudden cardiac death (e.g., prior MI, VT) → Combines ICD benefits with resynchronization

Procedure: Multiple leads placed in right atrium, right ventricle, and left ventricle (via coronary sinus); paces both ventricles simultaneously to restore coordinated contraction

Timing of Device Discussion

• Discuss ICD/CRT early (when LVEF ≤35%), but implant ≥40 days post-MI (allow time for recovery)

• Non-ischemic cardiomyopathy: Consider earlier implantation if LVEF remains ≤35% on GDMT

• Shared decision-making: Discuss benefits, risks, lifestyle limitations (avoid certain activities, MRI)

Volume Status Management: Chronic Heart Failure

Daily Weights

• Goal: Monitor fluid balance; weight gain >2-3 lbs in 1 day or >5 lbs in 1 week suggests fluid retention

• Action: May need diuretic adjustment or GDMT titration

Sodium Restriction

• Goal: 2-3 g/day sodium (helps prevent fluid retention)

• Education: Avoid processed foods, canned soups, fast food, high-sodium seasonings

Fluid Restriction

• Goal: <2 L/day fluid if symptomatic hyponatremia or severe HF

Diuretics for Chronic Management

Agent: Furosemide (most common) or torsemide (longer half-life, more predictable)

Dosing: Lowest dose needed to maintain euvolemia; adjust based on daily weights and symptoms

• E.g., furosemide 20-40 mg daily or BID (some patients on >200 mg daily)

Avoid: Excessive diuresis (volume depletion worsens renal perfusion, increases creatinine, activates RAAS)

BNP Monitoring and Follow-Up

B-type Natriuretic Peptide (BNP) or NT-proBNP:

• Elevated in ADHF and chronic HF

• Used to confirm diagnosis and guide therapy in some settings (guided therapy trials show modest benefit)

• Not routinely monitored in asymptomatic HFrEF on stable GDMT

When to check:

• Suspicion of ADHF

• Symptom worsening on stable GDMT (may indicate disease progression)

• GDMT uptitration titration confirmation (should decline with optimized therapy)

Discharge Planning and Outpatient Follow-Up

Before Discharge

1. GDMT optimized: On target doses of ACE-I/ARNi, beta-blocker, MRA, SGLT2i (as tolerated)

2. Patient education: Fluid/sodium restriction, daily weights, symptom recognition, when to seek care

3. Follow-up appointment: Primary care or cardiology within 1 week (check Cr/K on MRA, adjust diuretics if needed)

4. Medication reconciliation: Ensure patient has all meds; counsel on adherence

5. Device check: If ICD/CRT implanted, provide patient ID card, schedule device interrogation in 2-4 weeks

Outpatient Follow-Up

Frequency:

• Weekly phone checks × 2-4 weeks post-discharge (assess weight, symptoms, medication tolerance)

• Office visit 1-2 weeks post-discharge (physical exam, labs, GDMT optimization)

• Q3 months office visits for chronic HF (assess symptom status, labs, EF trending with repeat echo Q1-2 years)

Monitoring:

• Renal function and potassium (esp. with GDMT changes)

• Repeat echocardiogram at 3 months to assess LVEF response; if improving, may downstage HF severity

Cardiac Rehabilitation Referral

Benefits:

• Supervised exercise improves functional capacity

• Patient education on medications, diet, symptom recognition

• Psychological support for depression/anxiety (common in HF)

Indications: All HF patients, especially post-hospitalization for ADHF or post-MI

Complete Order Set for Acute and Chronic Heart Failure

Acute Decompensated Heart Failure (Floor Admission)

Labs: BNP/NT-proBNP, troponin, CBC, CMP, LFTs, ECG

Imaging: Chest X-ray, echocardiogram (if not recent; assess LVEF, diastolic dysfunction, valvular disease)

Monitoring: Continuous pulse oximetry, telemetry; daily weights, strict I&Os

Treatment: Furosemide IV 40-80 mg Q1-2H; IV nitroglycerin 10-200 mcg/min; oxygen to SaO2 >90%

Escalation: Consider CPAP/BiPAP if respiratory distress; ICU if cardiogenic shock or intubation needed

Optimization: Check GDMT; may need to uptitrate or initiate if first presentation

Follow-up: Discharge 48-72 hours after hemodynamic stability; outpatient cardiology in 1 week

Acute Decompensated Heart Failure (ICU/Cardiogenic Shock)

Monitoring: Intraarterial BP line, continuous cardiac monitoring, Swan-Ganz catheter (assess cardiac output, filling pressures)

Labs: BNP, troponin, CBC, CMP, LFTs, lactate, ECG, echocardiogram

Imaging: Chest X-ray; consider cardiac catheterization (assess CAD, intracardiac pressures)

Treatment: IV diuretics (furosemide continuous infusion); IV vasodilator (nitroglycerin, nitroprusside); inotrope if SBP <90 (dobutamine, milrinone); vasopressor if refractory (norepinephrine)

Specialist: Cardiology and CCU management; consider mechanical support (IABP, VAD, ECMO) if refractory

Chronic HFrEF Optimization (Outpatient)

Labs: BNP (optional), CBC, CMP (monitor Cr/K with GDMT changes), lipid panel, HbA1c (if diabetic)

Imaging: Echocardiogram Q1-2 years (reassess LVEF)

Medications: ACE-I/ARNi + Beta-blocker + MRA + SGLT2i; diuretic PRN for congestion; consider ivabradine if HR >70

Monitoring: Monthly office visits × 3 months post-hospitalization; then Q3 months; daily home weights

Goals: Target GDMT doses, euvolemia, LVEF improvement on repeat echo, symptom reduction

Referral: Cardiac rehab, HF nurse education, dietitian (sodium restriction)

Advanced HFrEF with Reduced EF and Electrical Delay

Same as above PLUS:

Device referral: Cardiology evaluation for CRT-D (if LVEF ≤35%, QRS ≥120 ms, LBBB pattern on EKG)

Follow-up: Device implant Q2-4 weeks; device interrogation Q2-4 weeks post-implant

Monitoring: Post-implant echo to assess LVEF response and resynchronization benefit

2-Minute Screen

In the clinic or ER, prioritize:

1. Dyspnea etiology: HF (orthopnea/PND, rales, elevated JVP, peripheral edema) vs pneumonia/PE/asthma?

2. Assess volume status: JVP, lung exam (rales?), peripheral edema, orthostasis

3. EF classification: Order echo if not recent (HFrEF vs HFpEF guides GDMT)

4. ADHF trigger: Medication non-compliance, sodium excess, ACS, infection, AF, HTN crisis?

5. GDMT status: Is patient on ACE-I/ARNi, beta-blocker, MRA, SGLT2i? If not, initiate; if yes, uptitrate

6. Device status: LVEF ≤35%? Discuss ICD; QRS ≥120 ms? Discuss CRT

Don't-Miss Diagnoses

• Acute Coronary Syndrome (ACS): Triggering ADHF; elevated troponin, EKG changes, chest pain—urgent cardiology consult, catheterization

• Cardiogenic Shock: SBP <90, oliguria, altered mental status, cool extremities—ICU admission, inotropes/vasopressors, consider mechanical support

• Peripartum Cardiomyopathy: Pregnancy/postpartum period, acute HF with LVEF <35%—urgent imaging, consider ICD

• Fulminant Myocarditis: Viral prodrome, acute HF with LVEF <30%, elevated troponin—ICU, mechanical support, consider endomyocardial biopsy

• Acute Mitral Regurgitation: New murmur, sudden decompensation, flash pulmonary edema—urgent echo, consider surgical intervention

• Restrictive or Infiltrative Cardiomyopathy (Amyloidosis): HFpEF with preserved-to-normal EF, severe diastolic dysfunction, thickened walls—genetic testing, specialized imaging

Related Articles

• CCS Acute Kidney Injury: Floor Management & Workup

• CCS DVT and PE: Complete Anticoagulation Guide for Step 3

• CCS Pneumonia: CAP vs HAP vs VAP — Antibiotic Selection & Management

Ready to practice? The StudyCCS question bank includes 26+ heart failure cases covering ADHF stabilization, GDMT optimization, device decision-making, and management of cardiogenic shock with real-time scoring. Master acute decompensation, GDMT uptitration, and chronic HF management protocols today.